Genetische Erkrankungen

Roche announces global pre-approval access program (PAA, CUP) with Risdiplam

Good news came from Roche The pre-access only applies to all SMA TYPE 1 patients of all ages. After approval, everyone with SMA type 2 has access, please read more at SMA Europe Roche is currently offering patients with the most urgent medical need, Type 1 SMA, the opportunity for access to risdiplam based on […]